Objective: To assess the safety of combination eplrubicine, oxaliplatin and capecitabine (EOX) in unresectable advanced gasbic cancer. Patients and Methods: Sixty-eight patients with unresectable advanced gasbic cancer which had been treated with EOX between November 2011 and September 2012 at National Cancer Hospital, were retrospectively Investigated. Result: The highest incidence rates found at 50 to 59 years of age (35,5 percent), males are affected significantly more than females with a ratio is 1,72:1. Approximately 66 percent patients had been treated under the standard dose. Toxicity: Hemotologic toxicities were 69,1 percent. Grade 3/4 occurred in 32,3 percent of 60,1 percent patients had neuropenia. Anemia, thrombocytopenia occurred in 41,2 percent and 14,8 percent of patients, respectively and almost of them had grade 1/2. Most hepatotoxicity had grade 1/2 and neuphrotoxicity occurred in 10,3 percent of patients. Nausea, vomiting occurred in 27,9 percent and 8,8 percent of patients, respectively. The most frequent grade 3/4 drug-related adverse event was hand-foot syndrome (10,3 percent), but this was readily managed by treatment interruption and dose reduction. Conclusions: This EOX regimen shows an acceptable safety profile In unresectable gastric cancer patients but consideration the hematologic toxicities and hand-foot syndrome.
- Đăng nhập để gửi ý kiến